Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Top Biologic Industry Leaders to Convene at Biologics World Korea 2013

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Bringing together biologics drug innovators and bioprocess professionals from all around the world to discuss strategies in biosimilar and biobetter development, as well as cutting-edge advances in bioprocessing and bioanalytics.

The global biologics market is valued at an estimated US$149 bn and is expected to reach $230 bn by 2015. Monoclonal antibodies (mAbs) representing 32% of the market share is expected to be the fastest growing segment at 12.4% CAGR. South Korea’s biologics industry is well positioned to tap into this growing market. While Celltrion, Samsung Biologics and LG Life Sciences are grabbing the international headlines, innovative firms in South Korea such as Genexine, PharmAbcine, Alteogen and Ildong are building up an impressive innovative biologic pipeline that can rival international players.

The biologics landscape in South Korea is evolving fast. Knowing the who's and understanding the how's of the industry are crucial to stay competitive. Biologics World Korea 2013 conference will convene all these biologic players from South Korea and around the globe, to discuss the trend and challenges in biologic drug development. The conference will be chaired by Dr Byeong Doo Song, the President of Scripps Korea Antibody Institute.

The conference Keynote speaker is Dr Stanley Hong, the President of R&D of Celltrion, who led the first mAb biosimilar approval in the world. He said that the company will be interested in developing Biobetters. The company just launched its product, RemsimaTM worldwide and has already signed several distribution agreements with several leading pharma companies.

Another featured speaker is Dr Paul Coleman, the CEO of Hanwha Biologics, who successfully led the company in making its first landmark deal to license its newly developed biosimilar compound to Merck. Dr Coleman said that a key criterion in making a biosimilar globally available through partnerships is having the highest standards of quality in all aspects of the research and development processes. This is the key to success for the interest of companies who can access global markets. Hanwha Biologics has already garnered the interest of top companies in the world for its portfolio of other biosimilar compounds and is seeking to expand through further research and development of future biosimilar candidates.

The 2013 conference programme features industry visionary presentations from the Celltrion, Hanwha Biologics, Green Cross, Genexine, SK Chemicals, CJ CheilJedang, Mogam Biotech Institute, UCB Korea, Neopharm, KAIST, KRIBB, KBSI, PhamAbcine, Creagene, Merck Serono (USA), Protein Science Corporation (USA), NovImmune (Switzerland), Actokine (USA), Quest Pharma Tech (Canada), Wuxi AppTech Biologics (China) and many more. The conference programme runs on April 16-18 2013 at Sheraton Incheon Hotel. Technology providers such as BD Bioscience, Waters Korea, Dong-Il Shimadzu, Agilent Technologies and many others will also be there to showcase the latest solutions.

Since the inaugural success of Biologics World Korea 2012, the year 2013 conference will be more comprehensive to include biologic players at various stages of development. In the near term future, the innovations and partnerships will continue to drive the activities in this industry. With networking opportunities, presentation of valuable case studies and interactive discussion, the Biologics community can look forward to a fruitful gathering at the Biologics World Korea 2013. This conference aims to capture a holistic view of the issues challenging the industry, from market landscape to regulatory strategy, from bioprocessing to bioanalytics, from antibody engineering to clinical development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!